Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
June 10th, 2017
9.4K views
Here, we describe a combined flow cytometric cell sorting and low-input, next-generation library construction protocol designed to produce high-quality, whole-exome data from the Hodgkin Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (CHL).
Overview
This article presents a protocol for isolating Hodgkin Reed-Sternberg (HRS) cells from classical Hodgkin lymphoma (CHL) tumors, enabling high-quality whole-exome sequencing. The method focuses on generating tumor-derived DNA that is suitable for next-generation sequencing without pre-amplification.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Genomics
Background
- HRS cells are critical in understanding classical Hodgkin lymphoma.
- Identifying mutations can aid in diagnosis and treatment decisions.
- High-quality DNA is essential for accurate sequencing results.
- Current methods may not yield sufficient quality DNA for analysis.
Purpose of Study
- To isolate viable HRS cells from CHL tumors.
- To generate high-quality whole-exome sequencing data.
- To investigate key driver mutations and immuno escape mutations.
Methods Used
- Flow cytometric cell sorting to isolate HRS cells.
- Low-input next-generation library construction protocol.
- Analysis of tumor-derived DNA quality and purity.
- Sequencing to identify genetic alterations in CHL.
Main Results
- Successful isolation of high-quality HRS cell DNA.
- Identification of key mutations relevant to CHL biology.
- Potential implications for diagnosis and treatment strategies.
- Demonstrated method efficacy without pre-amplification.
Conclusions
- The protocol enhances the understanding of CHL at a genetic level.
- It may influence therapeutic decisions based on genetic findings.
- This approach could lead to improved patient outcomes through better classification and prognostication.
Frequently Asked Questions
What are Hodgkin Reed-Sternberg cells?
HRS cells are the malignant cells found in classical Hodgkin lymphoma, crucial for understanding the disease.
Why is high-quality DNA important?
High-quality DNA is essential for accurate next-generation sequencing, which informs diagnosis and treatment.
How does flow cytometry contribute to this study?
Flow cytometry allows for the precise isolation of viable HRS cells from tumor samples.
What implications does this research have for treatment?
Identifying mutations can guide therapy choices, potentially improving patient outcomes.
Is pre-amplification necessary in this method?
No, this method generates high-quality DNA suitable for sequencing without the need for pre-amplification.
What are the potential benefits of this protocol?
The protocol may enhance diagnosis, classification, and treatment strategies for Hodgkin lymphoma.
Executive Industry Relevance
Isolating rare tumor subpopulations like Hodgkin Reed-Sternberg cells enables precise molecular profiling for target validation in hematologic malignancies. This approach supports mechanistic de-risking by linking somatic alterations to therapeutic response, informing preclinical model selection and biomarker strategy. High-purity cell isolation combined with low-input sequencing expands the feasibility of genomic analysis in low-abundance cell types, improving predictive confidence in early discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by isolating malignant HRS cells from inflammatory backgrounds for somatic mutation analysis.
- Operational Value: Provides a reproducible method to concentrate viable tumor cells for downstream genomic applications.
- Scientific Value: Supports biological de-risking through identification of clonal driver mutations and copy number alterations in HRS cells.
Screening & Assay Development
- Scientific Value: Generates high-quality DNA suitable for hybridization capture of whole-exome or targeted panels, enabling reliable variant detection.
- Operational Value: Uses an optimized low-input library protocol requiring as little as 10 ng DNA, reducing reagent burden and increasing throughput.
- Scientific Value: Facilitates comparison against healthy intratumor T or B cells to distinguish somatic alterations from germline variation.
Translational & Preclinical Research
- Scientific Value: Identifies mutations associated with immune escape and drug resistance, informing target selection and combination therapy rationale.
- Operational Value: Enables longitudinal monitoring of clonal evolution and tumor content via B2M and CIITA alterations as biomarkers.
- Scientific Value: Supports preclinical model alignment by characterizing the genomic landscape of primary HRS cells.
Pipeline & Workflow Integration
The method integrates flow sorting and low-input sequencing to bridge early tumor interrogation with functional genomics, supporting hypothesis-driven target identification and validation.
- Discovery Biology: Enables isolation of viable HRS cells to test pathogenic mechanisms and clarify signaling dependencies in classical Hodgkin lymphoma.
- Screening: Produces sequencing-ready libraries with median 50–100X coverage, enabling quantitative comparison of mutational burden and structural variants.
- Analytics: Delivers somatic mutation, indel, and copy number data that help prioritize targets based on recurrence and functional impact.
- Translational Research: Links genomic findings to immuno-oncology targets and resistance mechanisms, supporting biomarker-driven preclinical advancement.
- Enterprise Reuse: Establishes a standardized workflow for rare cell genomic analysis applicable to other low-frequency tumor populations.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence by reducing noise from stromal and immune contaminants in bulk tumor analysis.
- Operational Value: Combines fluorescence-activated cell sorting with low-input library prep to maximize yield from limited sample material.
- Strategic Value: Informs go/no-go decisions by revealing clonal mutations and neoantigen potential early in target assessment.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on somatic alteration profiles and pathway enrichment.
Implementation Considerations
- Requires expertise in flow cytometry, antibody panel optimization, and sterile cell handling to maintain viability and purity.
- Dependent on access to a cell sorter with appropriate fluorescence detection and low-input library preparation equipment.
- Necessitates standardized sorting gates and compensation controls to ensure reproducibility across operators and sites.
- Requires validation of DNA quality and fragment size distribution post-cleanup to avoid sequencing artifacts like adapter dimers.
- Limited by the rarity of HRS cells (<1% of tumor), necessitating sufficient starting material for meaningful cell recovery.
Biopharma FAQs
Why is flow sorting critical for HRS cell isolation?
Flow sorting using eight antibodies and scatter parameters enables high-purity separation of rare HRS cells from inflammatory lymphocytes, which constitute over 99% of the tumor mass. This enrichment is essential for obtaining sufficient tumor-derived DNA for downstream genomic analysis.
How does low-input library construction enable exome sequencing of sorted cells?
The optimized protocol generates high-quality sequencing libraries from as little as 10 ng of input DNA, overcoming the typical 100–1,000 ng requirement for standard exome library prep. This allows successful hybridization capture and sequencing even with limited cell yields from sorting.
What quantitative measurements enable somatic variant calling in HRS cells?
Exome sequencing provides base-level resolution to detect somatic mutations, insertions, deletions, and copy number alterations when compared to matched intratumor T or B cell controls. A median depth of 50–100X across the target supports confident variant identification.
Why are replication requirements important for cross-functional validation?
Reproducible isolation and sequencing of HRS cells across experiments ensure that observed somatic alterations, such as clonal B2M and CIITA mutations, are not technical artifacts. Consistent results support reliable target validation and biomarker development.
What statistical analysis is needed before implementing this method in target discovery?
Analysis must include comparison of variant frequency against healthy intratumor controls to distinguish somatic events from germline variation, along with assessment of copy number significance and mutational burden (100–400 somatic mutations per exome) to prioritize drivers.
